HIBADH

Across TCGA pan-cancer cohorts, HIBADH RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of HIBADH’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where HIBADH RNA is repressed in tumor relative to normal tissue. In most cancer types HIBADH is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, LUAD, and KICH are the cancer types where HIBADH tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HIBADH RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−0.785	<.001	10	view →
LUAD	Male	II,III,IV	+0.907	<.001	9	view →
KICH	All	II,III,IV	−0.880	<.001	9	view →
COAD	All	All	+0.498	<.001	9	view →
UCEC	All	All	−0.883	<.001	6	view →
KIRP	Male	III,IV	−0.829	<.001	6	view →
BRCA	Female	II,III,IV	−0.462	<.001	6	view →
STAD	Male	II,III,IV	+0.690	.005	5	view →
THCA	Male	All	−0.480	<.001	5	view →
CHOL	All	All	−1.037	<.001	2	view →
BLCA	Male	IV	−0.985	.040	2	view →
LIHC	Female	II,III,IV	−0.541	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

HIBADH–KIRC

Open the KIRC breakdown →